CTIS2023-506827-26-00Active, not recruitingPhase 1
ong-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS) - NN9535-4352
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- ovo Nordisk A/S
- Enrollment
- 1,467
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Male or female, age =18 years at the time of signing informed consent, Diagnosed with type 2 diabetes mellitus., HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Phase 1
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2017-003619-20-SKovo Nordisk A/S1,400
Active, not recruiting
Phase 1
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2017-003619-20-PTovo Nordisk A/S1,500
Active, not recruiting
Phase 1
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2017-003619-20-CZovo Nordisk A/S1,500
Active, not recruiting
Phase 1
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2017-003619-20-GBovo Nordisk A/S1,500
Active, not recruiting
Phase 1
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2017-003619-20-LVovo Nordisk A/S1,500